Poster Session 11 – Wednesday, December 9, 2020: 8:00 AM CT
   
  Systemic Therapies II - New
PS11-01 Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial
Lopes Cardozo JMN, Byng D, Drukker CA, Schmidt MK, van 't Veer LJ, Cardoso F, Piccart M, Poncet C, Rutgers EJTh. Netherlands Cancer Institute, Amsterdam, Netherlands; Tergooi Hospital, Hilversum, Netherlands; Univ California San Francisco, San Francisco, CA; Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; EORTC Headquarters, Brussels, Belgium.
PS11-02 Comprehensive comparative analysis of invasive ductal and lobular breast cancer cases in Great Lakes Breast Cancer Consortium
Oesterreich S, Nasrazadani A, Zou J, Onger T, Wright M, Tseng G, Ramaswamy B, Lee AV, Williams N, Kruse M. UPMC Hillman Cancer Center, University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, PA; James Cancer Hospital/The Ohio State University Wexner Medical Center (OSU), Columbus, OH; James Cancer Hospital/The Ohio State University Wexner Medical Center (OSU), Columbus, PA.
PS11-03 Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: a subgroup analysis of germline <i>BRCA1</i> or <i>BRCA2</i> mutations from the phase 3 BROCADE3 trial 
Wildiers H, Ayoub J-P, Friedlander M, Kaufman B, Arun BK, Han HS, Puhalla SL, Maag D, Feng D, Ratajczak CK, Bach BA, Diéras V. University Hospitals Leuven, Leuven, Belgium; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Prince of Wales Clinical School, University of New South Wales and Prince of Wales Hospital, Sydney, Australia; Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; The University of Texas MD Anderson Cancer Center, Houston, TX; Moffitt Cancer Center, Tamp, FL; UPMC Hillman Cancer Center, Pittsburgh, PA; AbbVie Inc., North Chicago, IL; Institut Curie, Paris, France.
PS11-04 Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatment arms and molecular subtypes
Yu K, Basu A, Yau C, Wolf D, Hirst G, Sit L, O’Grady N, Brown T, I-SPY 2 Trial Investigators, DeMichele A, Berry D, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. UCSF, San Francisco, CA; University of Alabama, Tuscaloosa, AL; University of Pennsylvania, Philadelphia, PA; Berry Consultants LLC, Austin, TX; University of Minnesota, Minneapolis, MN.
PS11-05 Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer
Baird R, Oliveira M, Ciruelos Gil EM, Patel MR, de las Heras BB, Ruiz-Borrego M, García-Corbacho J, Armstrong A, Banerji U, Twelves C, Boni V, Incorvati J, Kabos P, Cohen AL, de Paula B, Capelán Rodríguez M, Wang JS, Hernando C, Gonzalez AF, Ruiz IV, Lai-Kwon J, Afghani A, Vaklavas C, Brier T, Fox S, Kirova B, Klinowska T, Leach C, Lindemann JPO, Mather R, Maudsley R, Morrow CJ, Sathiyayogan N, Sykes A, Zhang L, Hamilton E. Cancer Research UK, Cambridge Centre, Cambridge, United Kingdom; Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain; Florida Cancer Specialists/Sarah Cannon Research Institute/Sarasota Memorial Hospital, Sarasota, FL; Department of Medical Oncology, Hospital Clinico Universitario of Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain; Department of Medical Oncology, H U Virgen del Rocio, Seville, Spain; ICMHO Clinical Trials Unit, Hospital Clinic, Barcelona, Spain; The Christie NHS Foundation Trust and the Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom; Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom; St. James’s Hospital and University of Leeds, Leeds, United Kingdom; START Madrid, Centro Integral Oncologico Clara Campal (CIOCC), Hospital Universitario HM Sanchinarro, Madrid, Spain; Fox Chase Cancer Center, East Norriton-Hospital Outpatient Center, Philadelphia, PA; Division of Medical Oncology, University of Colorado, Boulder, CO; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Diane O’Connor Thompson Breast Cancer, Aurora, CO; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
PS11-06 Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
Rosen EY, Italiano A, Juric D, Reeves JA, Dima L, Brega N, Drilon A. Memorial Sloan Kettering Cancer Center, New York, NY; Early Phase Trials Unit, Institut Bergonie, Bordeaux, France; Massachusetts General Hospital Cancer Center, Boston, MA; Bayer HealthCare Pharmaceuticals, Whippany, NJ; Bayer Consumer Care AG, Basel, Switzerland; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
PS11-07 Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166
Liu JF, Zein IA, Dang T, Lyman SK, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton V, Hannah A; Boni V. Dana-Farber Cancer Institute, Boston, MA; CytomX Therapeutics, Inc., South San Francisco, CA; Virginia Cancer Specialists, Fairfax, VA; University of Wisconsin – Carbone Cancer Center, Madison, WI; Yale University School of Medicine, New Haven, CT; Rush University Medical Center, Chicago, IL; MD Anderson Cancer Center, Houston, TX; Sarah Cannon Research Institute UK Limited, London, United Kingdom; Barbara Ann Karmanos Cancer Institute, Detroit, MI; South Texas Accelerated Research Therapeutics (START) Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain.
PS11-08 Operational standardization and quality assurance yield high acceptance rate for breast MRI in the I-SPY 2 Trial
Gibbs J, Newitt DC, Watkins M, Li W, Cimino L, Li C, Onishi N, Wilmes LJ, Bareng TJ, Proctor E, LeStage B, Parker B, the I-SPY 2 Coodinators, the I-SPY 2 Imaging Working Group, Hylton NM. University of California, San Francisco, San Francisco, CA; American College of Radiology, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; University of Chicago Medicine, Chicago, IL.
PS11-09 Impact of <i>UGT1A1 </i>status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer
Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey L, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;Dana-Farber Cancer Institute, Boston, MA; Institut Curie, Paris, France; University Hospitals Leuven, Leuven, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Madrid, Spain; Centre Eugène-Marquis, Rennes, France; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Gianni Bonadonna Foundation, Milan, Italy; Institute Jules Bordet, Brussels, Belgium; Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Immunomedics, Morris Plains, NJ; Columbia University Medical Center, New York, NY.
PS11-10 A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
Aftimos P, Oliveira M, Punie K, Boni V, Hamilton E, Gucalp A, Shah P, Mina L, Sharma P, Bauman L, Campeau E, Attwell S, Snyder M, Norek K, Czibere A, Yu Y, Silverman MH, Lakhotia S, Domchek S, Litton J, Robson M. Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium; Vall d'Hebron Institute of Oncology, Barcelona, Spain; UZ Leuven, Leuven, Belgium; START, Madrid, Spain; Sarah Cannon Research Institute, Nashville, TN; Memorial Sloan Kettering Cancer Center, New York City, NY; Abramson Cancer Center University of Pennsylvania, Philadelphia, PA; Banner MD Anderson Cancer Center, Gilbert, AZ; University of Kansas Cancer Center, Westwood, KS; Zenith Epigenetics, San Francisco, CA; Zenith Epigenetics, Calgary, AB, Canada; Pfizer, Cambridge, MA; Pfizer, La Jolla, CA; University of Texas MD Anderson, Houston, TX.
PS11-11 Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with <i>PIK3CA</i>-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
Olivera M, Jhaveri K, Juric D, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Schmid P, Turner N, Varga A, Lei G, Royer-Joo S, Thomas P, Schutzman JL, Saura C. Medical Oncology Department, Vall d’Hebron University Hospital, Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Department of Medicine, Massachusetts General Hospital, Boston, MA; Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada; Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France; Department of Medicine, Columbia University Irving Medical Center, New York, NY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Centre for Experimental Cancer Medicine, Cancer Research UK Barts Centre, London, United Kingdom; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France; Biometrics, Roche Products Limited, Welwyn Garden City, United Kingdom; gRED: Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA; Early Development Clinical Safety/Product Development Safety, Genentech, Inc., South San Francisco, CA.
PS11-12 Statin use significantly improves outcome in luminal B relative to luminal A breast cancers
Redfern AD, Spalding LJ, Anderson RL, Martin H. University of Western Australia, Perth, Australia; Harry Perkins Institute of Medical Research, Perth, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Australia; Fiona Stanley Hospital, Perth, Australia.
PS11-13 Multidimensional molecular profiling of repeated metastatic TNBC biopsies in the intensive trial of omics <ITOMIC> safely guides treatment decisions
Burton KA, Konnick EQ, Blau S, Dorschner MO, Gralow J, Parulkar R, Mahen E, Spilman P, Parker S, Senecal FM, Pritchard C, Szeto C, Zhu J, Gadi VK, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA. Northwest Medical Specialties, Tacoma, WA; University of Washington, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; ImmunityBio, Santa Cruz, CA; University of California at Santa Cruz, Santa Cruz, CA; Nantomics/ImmunityBio, Culver City, CA.
PS11-14 Advanced precision health resources in the Susan G Komen Tissue Bank at the IU Simon Comprehensive Cancer Center
Bray SM, Wong SS, Parikh BG, Wood KC, Rysdyk ST, Henry JE, Marino N, Radovich M, Storniolo AMV. LifeOmic, Indianapolis, IN; Susan G Komen Tissue Bank at the IU Simon Comprehensive Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN.
PS11-15 Plinabulin and Pegfilgrastim (Plin+Peg) versus Peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain
Blayney DW, Ginn G, Huang L, Mohanlal RW. Stanford Cancer Institute, Stanford, CA; Statogen Consulting,LLC, Wake Forest, NC; Beyond Spring Pharmaceuticals, Inc., New York, NY; Beyond Spring Pharmaceuticals,Inc., New York, NY.
PS11-16 Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL
Thill M, Zahn M-O, Welt A, Stickeler E, Nusch A, Fietz T, Rauh J, Wetzel N, Kruggel L, Jänicke M, Marschner N, Harbeck N, Wöckel A, Decker T, OPAL study group. Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany; Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation Harz, Goslar, Germany; Universitätsklinikum Essen Innere Klinik Tumorforschung, Essen, Germany; Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin, Aachen, Germany; Praxis für Hämatologie und internistische Onkologie, Ratingen, Germany; Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie, Singen (Hohentwiel), Germany; GIM - Gemeinschaftspraxis Innere Medizin, Witten, Germany; iOMEDICO, Freiburg, Germany; Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany; Klinikum der Universität München, München, Germany; Universitätsklinikum Würzburg Frauenklinik und Poliklinik, Würzburg, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany.
PS11-17 Combination PI3K and NOS targeted therapy for metaplastic breast cancer
Reddy TP, Rosato RR, Guzman L, Wei W, Zhou J, Wang H, Piwnica-Worms H, Moulder S, Chang JC. Houston Methodist Research Institute, Houston, TX; Texas A&M Health Science Center College of Medicine, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Houston Methodist Cancer Center, Houston, TX.
PS11-18 Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): results of Phase I expansion cohorts
Dean E, Krebs MG, Im S-A, Campone M, Postel-Vinay S, Arkenau T, Lopez J, Abida W, Jodrell D, Lee K-W, Rha S, Kang I, Roylance R, Parr G, Smith C, Goldwin A, Sanay E, Lukashchuk N, Lau A, Pierce A, Loembe B. AstraZeneca, Cambridge, United Kingdom; The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom; Seoul National University Hospital, Seoul, Republic of Korea; Institut de Cancerologie de l'Ouest, Nantes, France; Institut Gustave Roussy, Paris, France; Sarah Cannon Research UK, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY;; Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; University of Southern California, Los Angeles, CA; University College London, London, United Kingdom.
PS11-19 Metformin improves the survival in Chinese early invasive breast cancer patients with type 2 diabetes mellitus
Hui T, Shang C, Song Z. Hebei Medical University 4th Hospital, Shijiahzhuang City, China.
PS11-20 Radiation therapy (RT) induced toxicity in advanced breast cancer (ABC) patients treated with CDK4/6 inhibitors (CDK4/6is)
Stjepanovic N, Thawer A, Nathoo D, Giffoni D, Romero M, Lott A, Eisen A, Pezo R, Jerzak K, Trudeau M, Gandhi S, Warner E. Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
PS11-21 First-line treatment trends in metastatic breast cancer before and at the early stage of the COVID-19 pandemic in the United States
Kurosky S, Liu X, Meche A, Levin R, Sullivan A, McRoy L. Pfizer Inc, New York, NY.
PS11-22 Lipophilic statins for prolonging dormancy and overall survival: A real-world retrospective investigation
Gomez Marti JL, Wells A. University of Pittsburgh, Pittsburgh, PA.
PS11-23 Current landscape in phase 3 trials in breast cancer at major oncology conferences
Bretas GA, Bines J, Saad2 ED. INCA - Instituto Nacional do Câncer, Rio de Janeiro, Brazil; Dendrix Research, São Paulo, Brazil.
PS11-24 Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: results of a single-arm pilot clinical trial
Jiang J. Army Medical University, Chongqing, China.
PS11-25 Pilot trial of priming with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency (DDRD) followed by cisplatin (cis) and nab paclitaxel (nab pac) in chemotherapy-pretreated metastatic triple negative breast cancer (metTNBC) pts
O'Shaughnessy J, San Roman Rodriguez E, Ontiveros P, Wenstrup R, Pramparo T, Lang J, Zismann V, Briones N, Hendricks W, Espina V, Mueller C, Levin MK. Baylor University Medical Center, Dallas, TX; Baylor Scott & White Research Institute, Dallas, TX; Epic Sciences, San Diego, CA; The Translational Genomics Research Institute, Phoenix, AZ; George Mason University, Fairfax, VA.
PS11-26 A Phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer
Osborne C, Richards DA, Wilks ST, Diab S, Juric D, Lathrop K, Silber A, Edenfield W, Aulakh A, Cho B, Xu B, Sun T, Ouyang Q, Shi Y, Stazzone K, Shi Z, Zhang L, Wang Y, Hamilton EP. Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Texas Oncology-Tyler, Tyler, TX; Texas Oncology-San Antonio Northeast, San Antonio, TX; Rocky Mountain Cancer Centers, Aurora, CO; Massachusetts General Hospital, Boston, MA; University of Texas Health Science Center San Antonio, San Antonio, TX; Yale Cancer Center, New Haven, CT; Greenville Health System - Cancer Institute, Greenville, SC; CARE Cancer Center, Fresno, CA; William Valley Cancer Institute and Research Center, Eugene, OR; Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; Liaoning Cancer Hospital, Shenyang, China; Hunan Cancer Hospital, Changsha, China; Sun Yat-sen University Affiliated Cancer Hospital, Guangzhou, China; InventisBio LLC, Florham Park, NJ; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
PS11-27 A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer
Francisco-Anderson L, Shariffudin S, Gardner H, Sandy P, Goldberg M, Kashyap S, Abdou M, Sizova M, Kravitz V, Ponichtera H, Carlson M, Argueta S, Davitt C, Parameswaran P, Chisamore M, Bodmer M, McHale D. Evelo Biosciences, Cambridge, MA; Merck, Kenilworth, NJ.
PS11-28 Efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer
Lu J, Blakely CM, Le Tourneau C, Waqar SN, Bauer TM, de Braud F, Hong DS, Spira A, Tan T, McCallum S, Osborne S, Simmons B, Barve M. USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA; Institut Curie, Paris Saclay University, Paris and Saint-Cloud, France; Washington University School of Medicine, St. Louis, MO; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Fondazione IRCCS Istituto Nazionale dei Tumori, and University of Milan, Milan, Italy; The University of Texas, M.D. Anderson Cancer Center, Houston, TX; Virginia Cancer Specialists Research Institute, Fairfax, VA; National Cancer Centre Singapore, Singapore, Singapore; Genentech Inc., South San Francisco, CA; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Mary Crowley Cancer Research Center, Dallas, TX.
PS11-29 A phase 2 study evaluating Orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)
Yardley DA, Young RR, Adelson KB, Silber AL, Kommor MD, Najera JE, Daniel DB, Peacock NW, Shastry M, Hainsworth JD, Burris, III HA. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; The Center for Cancer and Blood Disorders, Forth Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Cancer Centers of Southwest Oklahoma, Lawton, OK; Sarah Cannon Research Institute/Tennessee Oncology, Chattanooga, TN; Sarah Cannon Research Institute, Nashville, TN.
PS11-30 Can Metronomic Maintenance Therapy (MMT) after completion of standard therapy help prevent relapses in patients (Pts) with non-metastatic Triple-Negative Breast Cancer (TNBC)
Bajaj K, Banavali S. TATA Memorial Hospital, Mumbai, India.
PS11-31 Survival among female breast cancer patients who have survived a previous cancer
Pruitt SL, Zhu H, Heitjan D, Gerber DE, Maddineni B, Xiong D, Halm E, Murphy C. UT Southwestern Medical Center, Dallas, TX.
PS11-32 Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)
Hamilton E, Lee A, Swart R, Newton G, O'Connell B, Roberts J, Zhang H, Soliman H. Tennessee Oncology, Nashville, TN; UT Health East Texas HOPE Cancer Center, Tyler, TX; Arizona Oncology Associate PC HOPE, Tucson, AZ; Infinity Pharmaceuticals, Cambridge, MA; Moffitt Cancer Center, Tampa, FL.
PS11-33 A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients
Beeram M, Wang JS, Chalasani P, Mina L, Patnaik A, Pambid MR, Jayanthan A, Huynh M-m, Los G, Dunn SE, Dorr FA. START, San Antonio, TX; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; University of Arizona Cancer Center, Tucson, AZ; Banner MD Anderson, Gilbert, AZ; Phoenix Molecular Designs, Vancouver, BC, Canada; Phoenix Molecular Designs, San Diego, CA.
PS11-34 Time to completion of breast cancer treatment and survival
Pratt DA, Burneikis T, Tu C, Grobmyer SR. Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
PS11-35 Mipra, a window of opportunity study evaluating mifepristone treatment for postmenopausal breast cancer patients with higher levels of progesterone receptor isoform a than b 
Elia A, Vanzulli SI, Gass H, Lamb CA, Fabris VT, Martinez Vazquez P, Burruchaga J, Spengler E, Caillet Bois I, Castets A, Lovisi S, Liguori M, Pataccini G, Abascal MF, Novaro V, Acosta Haab G, Molinolo A, Rojas P, Lanari C. Instituto de Biología y Medicina Experimental, Ciudad Autónoma de Buenos Aires, Argentina; Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires, Argentina; Hospital de Agudos "Magdalena V de Martinez", General Pacheco, Tigre, Argentina; San Isidro Patologia (SIP), San Isidro, Argentina; Moores Cancer Center, University of California San Diego, San Diego, C.
PS11-36 First-in-human chimeric antigen receptor t cells target muc1 transmembrane cleavage product
Bamdad C, Stewart AK, Huang P, Smagghe BJ, Moe ST, Swanson TE, Jeon TG, Page DM, Grant TJ, Specht JM. Minerva Biotechnologies, Waltham, MA; Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
PS11-37 Veru-111 as an orally available tubulin inhibitor suppressing both taxane-sensitive and taxane-resistant triple-negative breast cancer
Li W, Deng S, Krutilina R, Miller D, Seagroves T. University of Tennessee HSC, Memphis, TN.